Welcome to our dedicated page for Tivic Health Systems SEC filings (Ticker: TIVC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tivic Health Systems, Inc. (TIVC) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered tools to help interpret complex documents. Tivic files a range of reports with the U.S. Securities and Exchange Commission that outline its immunotherapeutics strategy, licensing agreements, financings and governance matters.
Investors can review Tivic’s current reports on Form 8‑K, which describe material events such as the exclusive license and amended and restated license agreement for the TLR5 agonist programs Entolimod and Entolasta, the transfer of investigational new drug applications (INDs) for Entolimod, and the acquisition of contract development and manufacturing organization (CDMO) assets used to form Velocity Bioworks. Other 8‑K filings detail executive employment agreements, equity incentive plan amendments, transfer agent changes and shareholder meeting results.
Registration statements like the S‑1/A shed light on Tivic’s status as an emerging growth and smaller reporting company, the registration of common stock and warrants held by selling stockholders, and the structure of preferred stock and convertible securities. These documents help explain how Tivic raises capital to support its biologics and bioelectronic programs.
On this page, Stock Titan surfaces Tivic’s 10‑K annual reports and 10‑Q quarterly reports when available, which typically include risk factors, management’s discussion and analysis, and detailed descriptions of the company’s dual‑platform strategy in biologics and bioelectronic medicine. Form 4 and related ownership filings, when present, can be used to monitor insider equity transactions and incentive awards tied to Tivic’s equity plans.
Stock Titan enhances Tivic’s filings with AI-generated summaries that highlight key terms in license agreements, financing structures, and manufacturing commitments, helping readers quickly identify items such as Entolimod development milestones, Velocity Bioworks obligations, and voting outcomes from shareholder meetings. Real-time EDGAR updates ensure that new Tivic filings appear promptly, while structured views make it easier to navigate between 8‑K events, registration statements and periodic reports for a more complete understanding of TIVC’s regulatory and corporate history.
Tivic Health Systems, Inc. is changing its corporate name to Valion Bio, Inc., effective April 28, 2026, with its Nasdaq ticker symbol expected to switch from TIVC to VBIO. The company states that shareholder approval was not required and that the name change does not alter shareholder rights.
The rebrand highlights a shift from consumer medical devices to a late-stage biopharmaceutical model built around lead candidate Entolimod™, a TLR5 agonist with FDA Fast Track and Orphan Drug designations being advanced under the FDA Animal Rule for Acute Radiation Syndrome, and explored for chemotherapy-induced neutropenia. The company reports more than $140 million in cumulative development investment in Entolimod and over 15 years of development history. It is engaging BARDA and other U.S. agencies regarding potential Strategic National Stockpile procurement, which the company notes could represent a non-dilutive, potentially nine-figure revenue opportunity if a contract is secured.
Valion Bio also highlights its wholly owned CDMO subsidiary Velocity Bioworks, acquired in December 2025 for approximately $16.3 million, which recently completed a 200-fold manufacturing scale-up of Entolimod using 50-liter fermentation and is intended both to support internal supply and to serve third-party biotech clients.
Tivic Health Systems, Inc. is soliciting stockholder approval at its 2026 Annual Meeting for director election and multiple capital‑raising and governance actions.
The proposals include: (1) approving an amendment to the 2021 Equity Incentive Plan to add 2,581,608 shares (increasing the plan reserve to 3,219,566 shares); (2) ratifying its auditor; and (3) seeking Nasdaq shareholder approvals to permit future issuances upon conversion or exercise tied to the Series C Preferred financing (up to 75,000 shares of Series C for up to $75.0M, with a $2.2310 fixed conversion/exercise price), the Note Purchase (warrant capacity of 4,553,213 shares and total purchase price $16,253,147.10), and an Equity Line of Credit (up to $50M). The Board recommends voting FOR all proposals.
Tivic Health Systems, Inc. director Sheryle Bolton purchased 10,000 shares of Common Stock in an open-market transaction at $1.04 per share. Following this purchase, she holds 10,000 shares directly.
Tivic Health Systems, Inc. is registering for resale up to 956,222 shares of its common stock held by Tumim Stone Capital, LLC, consisting of 519,210 shares issuable under a Common Stock Purchase Agreement and 437,012 shares issuable upon exercise of a pre-funded warrant. The company will not receive proceeds from Tumim’s resale, though it may receive proceeds if it elects to sell shares to Tumim under the Purchase Agreement—the Purchase Agreement provides for up to $50.0 million of purchases over a 24-month commitment period, subject to an Exchange Cap, VWAP-based pricing formulas, and a beneficial ownership blocker (initially 4.99%, elected to 9.99%). Shares outstanding used in this prospectus: 2,877,926 prior and 3,834,148 after the assumed issuance described herein.
Tivic Health Systems, Inc. is registering 956,222 shares of common stock for resale by Tumim Stone Capital under an equity line arrangement. The shares include 519,210 shares that Tivic may sell to Tumim under a $50.0 million common stock purchase agreement and 437,012 shares issuable on exercise of a commitment pre-funded warrant.
Tivic will not receive proceeds from Tumim’s resale of these shares but may raise up to $50.0 million by selling stock to Tumim over 24 months, subject to ownership and Nasdaq exchange caps. If all 956,222 shares were issued, they would equal about 24.94% of the 3,834,148 shares assumed outstanding. The company has pivoted from bioelectronic devices to a late-stage biopharmaceutical focus around its TLR5 agonist Entolimod, launched CDMO subsidiary Velocity Bioworks, and executed significant reverse stock splits to maintain its Nasdaq listing.
Tivic Health Systems director Christina Rizopoulos Valauri made an open-market purchase of company stock. She bought 19,000 shares of Tivic Health Systems, Inc. Common Stock on April 1, 2026 at a price of $0.9478 per share. After this transaction, she directly owns 19,000 shares.
Tivic Health Systems, Inc. files its annual report outlining a major pivot from bioelectronic consumer devices to a late-stage biopharmaceutical strategy centered on Entolimod, a TLR5 agonist for Acute Radiation Syndrome and oncology-related complications such as neutropenia and thrombocytopenia. The company licensed Entolimod and next‑generation compound Entolasta in 2025 and created a CDMO subsidiary, Velocity Bioworks, supported by a financing package exceeding $90 million. Tivic reports net losses, an accumulated deficit and states there is substantial doubt about its ability to continue as a going concern, while also disclosing a material weakness in internal controls due to limited accounting staff. As of March 17, 2026, it had 2,877,926 shares outstanding and 52 employees, and is pursuing ARS and oncology opportunities, including potential U.S. government procurement for the Strategic National Stockpile.
Tivic Health Systems reported its full-year 2025 results and highlighted a major strategic shift into immunotherapy centered on its Entolimod™ platform and next-generation molecule Entolasta™. Management described 2025 as a defining year, securing global rights to Entolimod and advancing regulatory and development readiness.
The company is prioritizing Entolimod for acute radiation syndrome while planning to extend into oncology supportive care, initially targeting neutropenia via physician-sponsored trials expected later in the year. Through its Velocity Bioworks subsidiary, Tivic is vertically integrating manufacturing, positioning it as a standalone CDMO to both lower internal costs and pursue third-party revenue opportunities.
Tivic Health Systems, Inc. reported that Nasdaq has notified the company it is not in compliance with the Nasdaq Capital Market’s minimum bid price rule because its common stock closed below $1.00 per share for at least 30 consecutive business days. The stock remains listed for now, and Tivic has 180 days from March 19, 2026, through September 15, 2026, to regain compliance by having its closing bid at or above $1.00 for at least 10 consecutive business days. If it fails to do so, Nasdaq may grant an additional 180‑day grace period if other listing standards are met and Tivic indicates an intent to cure the deficiency; otherwise the shares could be subject to delisting, with a right of appeal.